Previous close | 3.1800 |
Open | 3.3300 |
Bid | 3.0100 x 3200 |
Ask | 3.0300 x 4000 |
Day's range | 3.3100 - 3.9500 |
52-week range | 2.8400 - 11.5000 |
Volume | |
Avg. volume | 961,017 |
Market cap | 201.836M |
Beta (5Y monthly) | 2.83 |
PE ratio (TTM) | N/A |
EPS (TTM) | -58.5300 |
Earnings date | 12 Jun 2024 - 17 Jun 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 31.85 |
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – The Canadian based leading global medical cannabis company, together with subsidiary company, MedReleaf Australia, have announced today the availability of medical cannabis pastilles for doctors to prescribe to patients in Australia. The novel product is produced by Aurora and distributed by MedReleaf Australia, a leading distributor of medical cannabis products with the number two position in the Australian market.
Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canada-based leading global medical cannabis company, today announced that it has repaid an aggregate of approximately $7.2 million (US$5.3 million), representing the final payment on the principal amount of its convertible senior notes ("Notes") at a total cash cost of $7.4 million (~US$5.5 million), including accrued interest. Following the completion of this repayment, Aurora's remaining debt1 of $47.9 million rela
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, today announced the partnership of Aurora Medicine UK Ltd with Script Assist, a cutting-edge medical cannabis prescription platform in the UK.